STOCK TITAN

Ligand Pharmaceuticals: Janus Henderson owns 4.6%

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Ligand Pharmaceuticals Incorporated (LGND) is the subject of Janus Henderson Group Ltd.'s amended report of beneficial ownership: 914,350 common shares, or 4.6% of the class. Janus Henderson reports shared voting and dispositive power over all 914,350 shares.

Beneficially owned common shares 914,350 shares Janus Henderson Group Ltd. report
Percent of class 4.6% 914,350 shares beneficially owned
Shared voting power 914,350 shares Janus Henderson Group Ltd. report
Shared dispositive power 914,350 shares Janus Henderson Group Ltd. report
Sole voting power 0 shares Janus Henderson Group Ltd. report
Sole dispositive power 0 shares Janus Henderson Group Ltd. report
beneficially owned regulatory
"securities beneficially owned, or deemed to be beneficially owned"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
shared voting power regulatory
"Shared voting power 914,350.00"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
shared dispositive power regulatory
"Shared dispositive power 914,350.00"
Managed Portfolios financial
"collectively referred to herein as Managed Portfolios"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many LGND shares does Janus Henderson Group Ltd. report beneficially owning?

Janus Henderson Group Ltd. reports beneficial ownership of 914,350 Ligand Pharmaceuticals common shares, equal to 4.6% of the class. It reports shared voting and dispositive power over all 914,350 shares.

Does any Managed Portfolio own more than 5% of LGND?

None of the Managed Portfolios owns more than 5% of Ligand Pharmaceuticals common stock. The portfolios hold the shares in their respective accounts and have the right to receive dividends and proceeds from sales.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google





53220K504

(CUSIP Number)
09/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G



JANUS HENDERSON GROUP Ltd.
Signature:Kristin Mariani
Name/Title:Head of North America Compliance
Date:11/16/2026
Exhibit Information

Exhibit 24: Power of Attorney Exhibit 99: Item 7

Keep reading